Oxaliplatin

製品コードS1224 バッチS122413

化学情報

	Synonyms	L-OHP,NSC 266046	Storage (From the date of receipt)	2 years 4°C(in the dark) powder
	化学式	C₈H₁₄N₂O₄Pt
	分子量	397.29	CAS No.	61825-94-3
Solubility (25°C)*	体外	Water	1.5 mg/mL warmed with 50ºC water bath (3.77 mM)
		DMF	1.25 mg/mL (3.14 mM)
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Oxaliplatin は autophagy を活性化する DNA alkylator です。Oxaliplatin は、RT4、TCCSUP、A2780、HT-29、U-373MG、U-87MG、SK-MEL-2、および HT-144 細胞において DNA 付加体を形成することにより、DNA/RNA Synthesis を阻害します。溶液は不安定なため、新鮮に調製する必要があります。DMSO は白金ベースの薬剤の溶解には推奨されません。薬剤の不活化を容易に招く可能性があります。
in vitro	The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. This compound induces primary and secondary DNA lesions that lead to cell apoptosis. It is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. This chemical effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively.
in vivo	A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. This compound (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. It is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C₂₆ colon carcinoma xenografts. This chemical induces impairment of retrograde neuronal transport in mice.
特徴	This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).

プロトコル(参考用のみ)

細胞アッセイ	細胞株	RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
	濃度	~100 μM
	反応時間	48 hours
	実験の流れ	The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after this compound exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding this chemical and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
動物実験	動物モデル	Human hepatocellular carcinoma xenografts HCCLM3
	投薬量	10 mg/kg
	投与方法	A weekly i.p. injection

参考

https://pubmed.ncbi.nlm.nih.gov/9834817/
https://pubmed.ncbi.nlm.nih.gov/11142694/
https://pubmed.ncbi.nlm.nih.gov/18043128/

https://pubmed.ncbi.nlm.nih.gov/8261411/
https://pubmed.ncbi.nlm.nih.gov/15619139/
https://pubmed.ncbi.nlm.nih.gov/19780708/
https://pubmed.ncbi.nlm.nih.gov/2675999/
https://pubmed.ncbi.nlm.nih.gov/23029238/
https://pubmed.ncbi.nlm.nih.gov/24812268/

+ 展开

カスタマーフィードバック

: Data from [J Proteomics, 2014, 10.1016/j.jprot.2014.10.009]

: Data from [Optical Methods for Tumor Treatment and Detection, 2013, 10.1117/12.2010730]

: , 2013, Dr. Edita Aksamitiene from Thomas Jefferson University

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Activation of lysosomal iron triggers ferroptosis in cancer [ Nature, 2025, 10.1038/s41586-025-08974-4]	PubMed: 40335696
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models [ Cancer Cell, 2025, S1535-6108(25)00223-5]	PubMed: 40513578
The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer [ Signal Transduct Target Ther, 2025, 10(1):341]	PubMed: 41083431
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy [ Cell Stem Cell, 2025, S1934-5909(25)00265-6]	PubMed: 40812300
Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink [ Adv Sci (Weinh), 2025, 12(10):e2411769]	PubMed: 39748450
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma [ J Exp Clin Cancer Res, 2025, 44(1):13]	PubMed: 39810240
Unveiling radiobiological traits and therapeutic responses of BRAFV600E-mutant colorectal cancer via patient-derived organoids [ J Exp Clin Cancer Res, 2025, 44(1):92]	PubMed: 40069844
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response [ Mol Syst Biol, 2025, 21(3):231-253]	PubMed: 39838187
Monitoring Response to Combinatorial Immunotherapies by Tracking both T Cells and Natural Killer Cells In Vivo via ImmunoPET-Raman Multimodal Gold Nanostars [ ACS Appl Mater Interfaces, 2025, 10.1021/acsami.5c11312]	PubMed: 41099635
CBX3 promotes multidrug resistance by suppressing ferroptosis in colorectal carcinoma via the CUL3/NRF2/GPX2 axis [ Oncogene, 2025, 10.1038/s41388-025-03337-9]	PubMed: 40089640

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。